O	0	3	The
O	4	9	ratio
O	10	12	of
O	13	21	positive
O	22	24	to
O	25	32	excised
O	33	38	nodes
O	39	49	identifies
O	50	54	high
O	54	55	-
O	55	59	risk
O	60	67	subsets
O	68	71	and
O	72	79	reduces
O	80	85	inter
O	85	86	-
O	86	99	institutional
O	100	111	differences
O	112	114	in
O	115	127	locoregional
O	128	138	recurrence
O	139	143	risk
O	144	153	estimates
O	154	156	in
O	157	163	breast
O	164	170	cancer
O	171	179	patients
O	180	184	with
O	185	186	1
O	186	187	-
O	187	188	3
O	189	197	positive
O	198	203	nodes
O	203	204	:
O	205	207	an
O	208	216	analysis
O	217	219	of
O	220	231	prospective
O	232	236	data
O	237	241	from
B-location	242	249	British
I-location	250	258	Columbia
O	259	262	and
O	263	266	the
O	267	268	M
O	268	269	.
O	269	270	D
O	270	271	.

O	272	280	Anderson
O	281	287	Cancer
O	288	294	Center
O	294	295	.

O	296	298	To
O	299	306	examine
O	307	310	the
B-intervention	311	316	power
I-intervention	317	319	of
I-intervention	320	323	the
I-intervention	324	329	nodal
I-intervention	330	335	ratio
I-intervention	336	337	(
I-intervention	337	339	NR
I-intervention	339	340	)
O	341	343	of
O	344	352	positive
O	352	353	/
O	353	360	excised
O	361	366	nodes
O	367	369	in
O	370	380	predicting
O	381	395	postmastectomy
O	396	408	locoregional
O	409	419	recurrence
O	420	421	(
O	421	424	LRR
O	424	425	)
O	426	428	in
O	429	437	patients
O	438	442	with
O	443	444	1
O	444	445	-
O	445	446	3
O	447	455	positive
O	456	461	nodes
O	462	463	(
O	463	464	N
O	464	465	+
O	465	466	)
O	467	470	and
O	471	473	in
O	474	485	identifying
O	486	493	cohorts
O	494	496	at
O	497	504	similar
O	505	509	risk
O	510	516	across
O	517	528	independent
O	529	533	data
O	534	538	sets
O	538	539	.

O	540	544	Data
O	545	549	from
B-intervention-participants	550	552	82
B-eligibility	553	561	patients
I-eligibility	562	566	with
I-eligibility	567	568	1
I-eligibility	568	569	-
I-eligibility	569	570	3
I-eligibility	571	572	N
I-eligibility	572	573	+
I-eligibility	574	581	treated
I-eligibility	582	589	without
I-eligibility	590	604	postmastectomy
I-eligibility	605	617	radiotherapy
I-eligibility	618	619	(
I-eligibility	619	623	PMRT
I-eligibility	623	624	)
I-eligibility	625	627	in
I-eligibility	628	631	the
I-eligibility	632	639	British
I-eligibility	640	648	Columbia
I-eligibility	649	650	(
I-eligibility	650	652	BC
I-eligibility	652	653	)
O	654	664	randomized
O	665	670	trial
O	671	675	were
O	676	684	compared
O	685	689	with
O	690	694	data
O	695	699	from
B-control-participants	700	703	462
O	704	712	patients
B-control	713	720	treated
I-control	721	728	without
I-control	729	733	PMRT
O	734	736	in
O	737	748	prospective
O	749	761	chemotherapy
O	762	768	trials
O	769	771	at
O	772	775	the
O	776	777	M
O	777	778	.
O	778	779	D
O	779	780	.

O	781	789	Anderson
O	790	796	Cancer
O	797	803	Center
O	804	805	(
O	805	810	MDACC
O	810	811	)
O	811	812	.

O	813	819	Kaplan
O	819	820	-
O	820	825	Meier
O	826	829	LRR
O	830	836	curves
O	837	841	were
O	842	850	compared
O	851	858	between
O	859	866	centers
O	867	872	using
O	873	876	the
O	877	885	absolute
O	886	892	number
O	893	895	of
O	896	897	N
O	897	898	+
O	899	902	and
O	903	908	nodal
O	909	915	ratios
O	915	916	.

O	917	920	The
B-outcome	921	927	median
I-outcome	928	934	number
I-outcome	935	937	of
I-outcome	938	945	excised
I-outcome	946	951	nodes
O	952	955	was
B-iv-cont-median	956	958	10
O	959	961	in
O	962	964	BC
O	965	968	and
B-cv-cont-median	969	971	16
O	972	974	in
O	975	980	MDACC
O	981	982	(
O	982	983	p
O	984	985	<
O	986	987	0
O	987	988	.
O	988	991	001
O	991	992	)
O	992	993	.

O	994	1003	Examining
O	1004	1007	LRR
O	1008	1010	by
O	1011	1017	number
O	1018	1020	of
O	1021	1022	N
O	1022	1023	+
O	1023	1024	,
O	1025	1028	the
B-outcome	1029	1031	10
I-outcome	1031	1032	-
I-outcome	1032	1036	year
I-outcome	1037	1040	LRR
I-outcome	1041	1045	rate
O	1046	1049	for
O	1050	1058	patients
O	1059	1063	with
O	1064	1065	1
O	1065	1066	-
O	1066	1067	3
O	1068	1069	N
O	1069	1070	+
O	1071	1074	was
O	1075	1081	higher
O	1082	1084	in
O	1085	1087	BC
O	1088	1096	compared
O	1097	1101	with
O	1102	1107	MDACC
O	1108	1109	(
B-iv-bin-percent	1109	1111	21
I-iv-bin-percent	1111	1112	.
I-iv-bin-percent	1112	1113	5
I-iv-bin-percent	1113	1114	%
O	1115	1117	vs
O	1117	1118	.
B-cv-bin-percent	1119	1121	12
I-cv-bin-percent	1121	1122	.
I-cv-bin-percent	1122	1123	6
I-cv-bin-percent	1123	1124	%
O	1124	1125	;
O	1126	1127	p
O	1128	1129	=
O	1130	1131	0
O	1131	1132	.
O	1132	1134	02
O	1134	1135	)
O	1135	1136	.

O	1137	1144	However
O	1144	1145	,
O	1146	1150	when
O	1151	1160	examining
O	1161	1164	LRR
O	1165	1170	using
O	1171	1173	NR
O	1173	1174	,
O	1175	1177	no
O	1178	1189	differences
O	1190	1194	were
O	1195	1200	found
O	1201	1208	between
O	1209	1221	institutions
O	1221	1222	.

O	1223	1225	In
B-outcome	1226	1234	patients
I-outcome	1235	1239	with
I-outcome	1240	1242	NR
I-outcome	1243	1244	<
I-outcome	1245	1247	or
I-outcome	1248	1249	=
I-outcome	1250	1251	0
I-outcome	1251	1252	.
I-outcome	1252	1254	20
O	1254	1255	,
O	1256	1259	the
B-outcome	1260	1262	10
I-outcome	1262	1263	-
I-outcome	1263	1267	year
I-outcome	1268	1271	LRR
I-outcome	1272	1276	rate
O	1277	1280	was
B-iv-bin-percent	1281	1283	17
I-iv-bin-percent	1283	1284	.
I-iv-bin-percent	1284	1285	7
I-iv-bin-percent	1285	1286	%
O	1287	1289	BC
O	1290	1292	vs
O	1292	1293	.
B-cv-bin-percent	1294	1296	10
I-cv-bin-percent	1296	1297	.
I-cv-bin-percent	1297	1298	9
I-cv-bin-percent	1298	1299	%
O	1300	1305	MDACC
O	1306	1307	(
O	1307	1308	p
O	1309	1310	=
O	1311	1312	0
O	1312	1313	.
O	1313	1315	27
O	1315	1316	)
O	1316	1317	.

O	1318	1320	In
B-outcome	1321	1329	patients
I-outcome	1330	1334	with
I-outcome	1335	1337	NR
I-outcome	1338	1339	>
I-outcome	1340	1342	or
I-outcome	1343	1344	=
I-outcome	1345	1346	0
I-outcome	1346	1347	.
I-outcome	1347	1349	20
O	1349	1350	,
O	1351	1354	the
B-outcome	1355	1357	10
I-outcome	1357	1358	-
I-outcome	1358	1362	year
I-outcome	1363	1366	LRR
I-outcome	1367	1371	rate
O	1372	1375	was
B-iv-bin-percent	1376	1378	28
I-iv-bin-percent	1378	1379	.
I-iv-bin-percent	1379	1380	7
I-iv-bin-percent	1380	1381	%
O	1382	1384	BC
O	1385	1387	vs
O	1387	1388	.
B-cv-bin-percent	1389	1391	22
I-cv-bin-percent	1391	1392	.
I-cv-bin-percent	1392	1393	7
I-cv-bin-percent	1393	1394	%
O	1395	1400	MDACC
O	1401	1402	(
O	1402	1403	p
O	1404	1405	=
O	1406	1407	0
O	1407	1408	.
O	1408	1410	32
O	1410	1411	)
O	1411	1412	.

O	1413	1415	On
O	1416	1419	Cox
O	1420	1430	regression
O	1431	1439	analysis
O	1439	1440	,
O	1441	1443	NR
O	1444	1447	was
O	1448	1449	a
O	1450	1458	stronger
O	1459	1469	prognostic
O	1470	1476	factor
O	1477	1485	compared
O	1486	1490	with
O	1491	1497	number
O	1498	1500	of
O	1501	1502	N
O	1503	1504	+
O	1504	1505	.

O	1506	1508	In
O	1509	1517	patients
O	1518	1522	with
O	1523	1524	1
O	1524	1525	-
O	1525	1526	3
O	1527	1528	N
O	1528	1529	+
O	1529	1530	,
O	1531	1541	evaluating
O	1542	1547	nodal
O	1548	1558	positivity
O	1559	1564	using
O	1565	1567	NR
O	1568	1575	reduced
O	1576	1581	inter
O	1581	1582	-
O	1582	1595	institutional
O	1596	1607	differences
O	1608	1610	in
O	1611	1614	LRR
O	1615	1624	estimates
O	1625	1629	that
O	1630	1633	may
O	1634	1639	exist
O	1640	1643	due
O	1644	1646	to
O	1647	1657	variations
O	1658	1660	in
O	1661	1668	numbers
O	1669	1671	of
O	1672	1677	nodes
O	1678	1685	excised
O	1685	1686	.

O	1687	1692	Nodal
O	1693	1698	ratio
O	1699	1700	>
O	1700	1701	0
O	1701	1702	.
O	1702	1704	20
O	1705	1708	was
O	1709	1719	associated
O	1720	1724	with
O	1725	1728	LRR
O	1729	1730	>
O	1730	1732	20
O	1732	1733	%
O	1733	1734	,
O	1735	1745	warranting
O	1746	1750	PMRT
O	1751	1764	consideration
O	1764	1765	.

O	1766	1771	Nodal
O	1772	1777	ratio
O	1778	1781	may
O	1782	1784	be
O	1785	1791	useful
O	1792	1795	for
O	1796	1809	extrapolating
O	1810	1814	data
O	1815	1819	from
O	1820	1831	prospective
O	1832	1838	trials
O	1839	1841	to
O	1842	1850	clinical
O	1851	1860	practices
O	1861	1863	in
O	1864	1869	which
O	1870	1878	axillary
O	1879	1886	staging
O	1887	1893	extent
O	1894	1898	vary
O	1898	1899	.
